&nbsp;

BiopsyAddendeumTemplate

May 2020

Regimen

AZCTVENE

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Palliative

Funding:

New Drug Funding Program

Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia

Drugs Used:

azaCITIDine,

venetoclax

Quick Link(s):

Regimen Monograph

Aug 2022

Document

ABVD.pdf

Sep 2020

Document

ABVD-FR.pdf

Sep 2020

Guidelines and Advice

Best-Practice Guidance for Radiation Treatment Plan Physics Review

Status: Current

Apr 2020

Guidelines and Advice

Best Practice Guidance for Patient-Specific Quality Assurance for IMRT and VMAT Plan Delivery Verification

Status: Current

Oct 2019

Document

BMT F 047 CAR T Referral Form v1.0.pdf

Oct 2020

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), according to clinical criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Jul 2024

Regimen

ACAL+OBIN

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded),

oBINutuzumab (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2020

Regimen

ACAL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2020

Regimen

ALPEFLVS

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

fulvestrant

Drugs Used:

fulvestrant,

alpelisib (Unfunded)

Quick Link(s):

Regimen Monograph

Jul 2023

Document